维普中文期刊产品整合服务
48篇 您的检索式:作者名="Haelst"
    题名 作者 年代 出处 被引量
1Priority setting for existing chemicals : The European Union risk ranking method 显示文摘HANSEN B J VAN HAELST A G VAN LEEUWEN K 1999Environ Toxicol Chem1999,18,:1
2Selective serotonin reuptake inhibitors and intraoperative blood pressure显示文摘van Haelst IM van Klei WA Doodeman H J 0,,02:1
3Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Proce- dures: A Meta-analysis 显示文摘Weem SMOP Haelst STWV Ruijter HMD 2016European Journal of Vascular & Endo- vascular Surgery2016,52,2:1
4No long-lasting or intermittent mast cell activation in acute coronary syndromes显示文摘Van Haelst PL Timmer JR Grijns HJGM Kauffman HF Gans ROB van Doormaal JJ 2001Internat J Cardiol2001,78,:1
5The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress 显示文摘Mulder D J van Haelst PL Wobbes MH 2007Cardiovasc Drugs Ther2007,21,2:1
6The management of keratocysts显示文摘Voorsmit RACA Stoelinga PJW van Haelst UJGM 1981J Maxillofac Surg1981,9,:1
7Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholestelolaemia显示文摘Haelst PL van Doormaal JJ van Asselbergs FW 2003Clin Sci2003,104,:1
8Priority setting for existing chemicals: European Union risk ranking method显示文摘Hansen B G Van Haelst A G Van Leeuwen K 1999Environmental Toxicology and Chemistry1999,18,4:1
9Methotrexate maintenance therapy and liver damage in psoriasis显示文摘van de Kerkhof PC Hoefnagels WH van Haelst UJ 1985Clin Exp Dermatol1985,10,3:1
10Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin - 10 production after lipopolysaccharide stimulation 显示文摘Van Haelst PL Tervaert JW Bijzet J 2004Clin Exp Immunol2004,138,2:1
11Ablepharnn- Macrostomia syndrome--extension of the phenotype 显示文摘Kallish S McDonald-McGinn DM van Haelst MM el al 2011Am J Med Genet A2011,155,12:1
12The management of ker- atocysts显示文摘Voorsmit RA Stoelinga PJ van Haelst UJ 1981J Maxillofac Surg1981,9,4:1
13Priority setting for existing chemicals : European Union riskranking method 显示文摘HANSEN B J VAN HAELST A G Van LEEUWEN K 1999Environmental Toxicology and Chemistry1999,18,4:1
14Priority setting for existing chemicals : European Union risk rank- ing method 显示文摘HANSEN B G VAN HAELST A G VAN LEEUWEN K 1999Environmental Toxicology and Chemistry1999,18,4:1
15Long - term sur- vival in hilar cholangiocarcinoma also possible in unresectable patients显示文摘Ruys A T van Haelst S Busch O R 2012World journal of surgery2012,36,9:1
16Pain treatment following knee and hip replacement surgery 显示文摘Van Haelst IM Bocxe JS Burger B J 2009Ned Tijdschr Geneeskd2009,153,:1
17Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation显示文摘Van Haelst PL Tervaert JW Bijet J 0,,02:1
18Antineutro- phil cytoplasmatic antibodies in patients with premature ather- osclerosis: prevalence and association with risk factors显示文摘Haelst PL Asselbergs FW Doormaal JJ 2002J Intern Med2002,251,1:1
19Circulating monocytes in patients with acuter coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation 显示文摘Van Haelst PL Tervaert JW Bijzet J 2004Clin Exp Immunol2004,138,2:1
20Pain treatment follow-ing knee and hip replacement surgery显示文摘van Haelst IM Bocxe JS Burger B J 2009Ned Tijdschr Geneeskd2009,,153:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费